<code id='03B76A1B6C'></code><style id='03B76A1B6C'></style>
    • <acronym id='03B76A1B6C'></acronym>
      <center id='03B76A1B6C'><center id='03B76A1B6C'><tfoot id='03B76A1B6C'></tfoot></center><abbr id='03B76A1B6C'><dir id='03B76A1B6C'><tfoot id='03B76A1B6C'></tfoot><noframes id='03B76A1B6C'>

    • <optgroup id='03B76A1B6C'><strike id='03B76A1B6C'><sup id='03B76A1B6C'></sup></strike><code id='03B76A1B6C'></code></optgroup>
        1. <b id='03B76A1B6C'><label id='03B76A1B6C'><select id='03B76A1B6C'><dt id='03B76A1B6C'><span id='03B76A1B6C'></span></dt></select></label></b><u id='03B76A1B6C'></u>
          <i id='03B76A1B6C'><strike id='03B76A1B6C'><tt id='03B76A1B6C'><pre id='03B76A1B6C'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:fashion    Page View:8241
          In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp.
          Scott Olson/Getty Images

          WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

          The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends. 

          advertisement

          The negotiated prices won’t take effect until 2026. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more
          Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma
          Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo

          read more
          State Dept. review finds Biden bears some blame for Afghanistan failures
          State Dept. review finds Biden bears some blame for Afghanistan failures

          3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

          read more

          VC firm RA Capital starts a new synthetic biology incubator

          AdobeVenturecapitalfirmRACapitalisstartinganewincubator,settingthestageforthefirmtocreatenewstartups